AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, SeasonalHay Fever
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 302
- Registration Number
- NCT00659841
- Locations
- 🇺🇸
Altana/Nycomed, San Antonio, Texas, United States
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 122
- Registration Number
- NCT00658021
- Locations
- 🇿🇦
Research Site, Verulam, South Africa
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
Phase 3
Completed
- Conditions
- Non-metastatic Prostate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3618
- Registration Number
- NCT00657904
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease
Phase 3
Completed
- Conditions
- Myocardial IschaemiaCoronary Artery Disease
- Interventions
- Behavioral: Cholesterol lowering diet
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT00657527
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT00658255
Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
Phase 3
Completed
- Conditions
- HypercholesterolemiaCarotid Artery Stenosis
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00654394
IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin
Phase 3
Completed
- Conditions
- Fredrickson Type IIa & Type IIb Dyslipidaemia
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT00654446
STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5625
- Registration Number
- NCT00654537
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 940
- Registration Number
- NCT00654485
Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4875
- Registration Number
- NCT00654407
© Copyright 2025. All Rights Reserved by MedPath